KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Shares Issued (2016 - 2025)

Gilead Sciences (GILD) has disclosed Shares Issued for 17 consecutive years, with $32.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 81.5% year-over-year to $32.0 million, compared with a TTM value of $408.0 million through Dec 2025, down 3.32%, and an annual FY2025 reading of $408.0 million, down 3.32% over the prior year.
  • Shares Issued was $32.0 million for Q4 2025 at Gilead Sciences, down from $97.0 million in the prior quarter.
  • Across five years, Shares Issued topped out at $252.0 million in Q1 2025 and bottomed at $3.0 million in Q2 2022.
  • Average Shares Issued over 5 years is $77.0 million, with a median of $70.0 million recorded in 2021.
  • The sharpest move saw Shares Issued skyrocketed 1366.67% in 2022, then tumbled 85.23% in 2023.
  • Year by year, Shares Issued stood at $12.0 million in 2021, then surged by 1366.67% to $176.0 million in 2022, then crashed by 85.23% to $26.0 million in 2023, then soared by 565.38% to $173.0 million in 2024, then crashed by 81.5% to $32.0 million in 2025.
  • Business Quant data shows Shares Issued for GILD at $32.0 million in Q4 2025, $97.0 million in Q3 2025, and $27.0 million in Q2 2025.